Peptide and Hormone Therapy
We don’t sell supplements. We engineer cellular transformation. Unlock the signaling power of peptides to accelerate repair, optimize metabolic function, and defy the standard rate of aging.
The Paradigm Shift in Medicine
For decades, medicine relied on blocking receptors. Today, we stand on the precipice of the ‘Bioregulatory Era.’ Peptides are precise signaling keys — short-chain amino acid sequences that unlock your body’s dormant mechanisms for repair, lipolysis, and hormonal homeostasis. This is biological architecture.
The "Wolverine" Protocol
BPC-157 + TB-500 | Musculoskeletal Reconstruction
Known as the ‘Ultimate Injury Repair’ stack, this combination accelerates the healing of soft tissues (tendons, ligaments, cartilage) that traditionally exhibit poor reparative potential.
Reprogramming Fibroblasts
BPC-157 fundamentally alters the gene expression of tendon fibroblasts. It upregulates Growth Hormone Receptors (GHR) on the cell surface⁷, effectively ‘tuning’ the injured tissue to listen more intently to the body’s natural repair signals via the JAK2 pathway.
Angiomodulation
Ischemic (low oxygen) tissue cannot heal. BPC-157 interacts with the NO-VEGF axis to promote angiogenesis (new blood vessel formation)⁹, building the vascular scaffolding necessary to deliver nutrients to the injury.
Cellular Mobilization
TB-500 (Thymosin Beta-4) acts as the ‘mechanic.’ It sequesters actin to drive rapid cytoskeletal remodeling, significantly increasing the migration speed of cells to the wound bed¹⁶.
Clinical Result
Rapid Tissue Bonding. In trials involving transected tendons, this stack consistently resulted in superior load-to-failure strength and reduced inflammatory infiltrates compared to controls.
Metabolic Engineering
AOD-9604 | Targeted Lipolysis
AOD-9604 is a modified fragment (amino acids 177–191) of the Human Growth Hormone molecule. It retains the fat-burning potency of HGH without the insulin resistance or mitogenic risks.
Beta-3 Adrenergic Pathway
AOD-9604 functions as a ‘lipolytic trigger’ by upregulating Beta-3 receptors specifically found on fat cells³⁰. This stimulates the release of fatty acids (lipolysis) while inhibiting the formation of new fat (lipogenesis).
Safety Advantage
Unlike whole HGH, AOD-9604 does not impair glucose tolerance or spike IGF-1 levels²⁸.
Clinical Result
In the Phase 2b ‘OPTIONS’ study involving 536 patients, the therapeutic dose resulted in significant weight loss over 12 weeks compared to placebo, with a safety profile indistinguishable from placebo³³.
Neuroendocrine Restoration
CJC-1295 + Ipamorelin | Anti-Aging
Aging is characterized by ‘Somatopause’ — the progressive decline in Growth Hormone. This protocol restores the body’s youthful, pulsatile release of GH without the side effects of synthetic replacement.
The Amplifier (CJC-1295)
A long-acting analog of GHRH. It amplifies the signal sent to the pituitary, increasing the basal levels of IGF-1 and priming the gland for synthesis³⁵.
The Trigger (Ipamorelin)
A selective mimetic of ghrelin. It acts as the specific trigger to release GH pulses. Uniquely, it does not spike cortisol or prolactin³⁹, making it the safest option for long-term therapy.
Clinical Result
Deep Wave Sleep — GHRH is a somnogenic factor. Research confirms that stimulating this pathway increases the duration of Slow-Wave Sleep⁴¹, the critical phase for cognitive clearing and physical recovery.
Systemic Cytoprotection
BPC-157 Standalone | Gut Health & Inflammation
Originally isolated from gastric juice, BPC-157 demonstrates a profound ability to heal the epithelial lining of the gastrointestinal tract.
The NSAID Antidote
BPC-157 is the only known agent capable of reversing severe gastrointestinal toxicity caused by NSAIDs (like Ibuprofen). Research confirms its ability to heal gastric ulcers and prevent liver lesions by maintaining endothelial integrity³.
Reversing "Leaky Gut"
By interacting with the nitric oxide (NO) system, BPC-157 stabilizes the junction between intestinal cells. This mitigates ‘intestinal permeability,’ preventing toxins from leaking into the bloodstream¹³.
Clinical Result
Ideal for athletes with high NSAID usage, patients with IBS/IBD symptoms, or those seeking to reduce systemic inflammation originating from the gut-brain axis.
The "Triple Agonist"
Retatrutide | Next-Gen Metabolic Control
The successor to Semaglutide and Tirzepatide. A single molecule that activates three distinct hormone receptors (GLP-1, GIP, and Glucagon) to revolutionize body composition.
The Glucagon Differentiation
While previous drugs reduced appetite (GLP-1/GIP), Retatrutide adds Glucagon Receptor (GCGR) agonism. This critical third pathway increases energy expenditure (resting metabolic rate) and actively mobilizes liver fat.
Clinical Efficacy
In Phase 2 clinical trials published in the New England Journal of Medicine, Retatrutide demonstrated up to 24% body weight reduction over 48 weeks — efficacy levels previously only achievable through bariatric surgery⁵⁵.
Clinical Result
Beyond weight loss, the triple-agonist action has shown profound improvements in lipid profiles, insulin sensitivity, and the rapid reduction of hepatic steatosis (fatty liver).
US-Based Regulation
We strictly adhere to US regulations. We only utilize prescription-grade peptides from regulated compounding pharmacies. We do not touch ‘research chemicals’ or grey-market imports.
Purity & Potency
Every vial is third-party tested for purity and concentration. We provide clear dosing guidelines and use bacteriostatic water for reconstitution to ensure stability and safety.
Scientific References
- [3] Sikiric et al. (2013). "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design.
- [7] Chang et al. (2014). "BPC 157 Induced the Expression of Growth Hormone Receptor in Tendon Fibroblasts." Molecules.
- [9] Lee et al. (2021). "Intra-Articular Injection of BPC-157 for Multiple Types of Knee Pain." Alternative Therapies.
- [13] Park et al. (2020). "BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability." Current Pharmaceutical Design.
- [16] Huff et al. (2001). "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." FASEB Journal.
- [28] Heffernan et al. (2001). "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology.
- [30] Heffernan et al. (2001). "AOD9604 lipid metabolism following chronic treatment in obese mice."
- [33] Metabolic Pharmaceuticals. (2004). "The OPTIONS Study: Phase 2b Results." (ASX Report)
- [35] Teichman et al. (2006). "Prolonged stimulation of GH and IGF-I secretion by CJC-1295." JCEM.
- [39] Raun et al. (1998). "Ipamorelin, the first selective growth hormone secretagogue." European J. Endocrinology.
- [41] Steiger et al. (1998). "GHRH and sleep regulation." American J. Physiology.
- [55] Jastreboff et al. (2023). "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." NEJM.
The services and products provided by Culture OC are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is for educational purposes only.
Incorporating peptides has taken things to another level — better energy, faster healing, and overall optimization.
— Steve Gonzalez
Ready to Explore Peptide Therapy?
Book a free evaluation call with Troy. He’ll tell you if peptide therapy is right for your situation.
Book Free EvaluationOr call (949) 751-1027